Clinical effects and applications of the gut microbiome in hematologic malignancies. Issue 5 (28th December 2020)

• Record Type: Journal Article
• Authors: D'Angelo, Christopher R.; Sudakaran, Sailendharan; Callander, Natalie S.
• Is Part Of: Cancer. Volume 127:Issue 5(2021)
• Page Start: 679
• Page End: 687
• Publication Date: 2020-12-28
• Subjects: butyrate -- gut microbiome -- hematologic malignancies -- review -- translational research; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33400
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : The gut microbiome and its effects on host immunity have exciting implications for cancer prognosis and therapy. Examples in allogeneic hematopoietic stem cell transplantation (allo‐SCT) demonstrate the role of the gut microbiome as a biomarker for clinical outcomes, and animal models demonstrate how microbiota manipulation may augment therapeutic responses. There are multiple mechanisms that gut microbiota may have in affecting distant tumor environments, including control of cytokine release, dendritic cell activation, and T‐cell lymphocyte stimulation. Recently, there has been a marked interest in understanding interactions between host and microbiome in hematologic malignancies. This review summarizes the current understanding of the gut microbiome and its impact on leukemia, lymphoma, multiple myeloma, and allo‐SCT and highlights several broad methods for targeting the gut microbiome in therapeutic trials. Abstract : The gut microbiome is an emerging and exciting topic in cancer research. This review summarizes the current state of clinical research and implications for the gut microbiome in the specific context of hematologic malignancies.